Methylene blue is usually described as a nootropic with a long medical history. In psychiatry it has a more specific and more interesting record than that framing suggests. It has been tested in bipolar disorder in controlled trials, twice in the 1980s and again in a modern randomized crossover study, and a 2024 neuroimaging trial went looking for the mechanism. This is the strongest human psychiatric evidence attached to the compound, and it is still narrower than most people assume.
Key Takeaways
- A two-year double-blind crossover trial published in 1986 tested methylene blue as prophylaxis in manic-depressive illness, making this one of the oldest controlled psychiatric uses of the compound.
- A 2017 randomized crossover study in the British Journal of Psychiatry tested methylene blue as an add-on for residual symptoms in bipolar disorder, with the clearest signal in anxiety and depressive symptoms rather than mania.
- A 2024 quantitative neuroimaging RCT found an altered oxidative neurometabolic response to methylene blue in bipolar disorder, which is mechanistic evidence rather than a clinical outcome.
- Every one of these studies used methylene blue alongside existing psychiatric medication, under supervision, not as a replacement for it.
- The serotonin syndrome interaction is the dominant safety issue here, because the population being studied is the population most likely to be taking serotonergic antidepressants.
Why Anyone Tried This in the First Place
The interest is old. Methylene blue was investigated for psychiatric use in the era when the boundaries between dyes, antimalarials, and psychotropics were still being worked out, and phenothiazine antipsychotics are structurally related to it. The mechanistic case rests on two properties: it is a monoamine oxidase inhibitor, which is a recognised antidepressant mechanism, and it acts as an electron carrier in mitochondria, which connects to a body of work implicating mitochondrial dysfunction in bipolar disorder.
Those are two quite different rationales, and the literature has never fully separated them.
The 1980s Trials
A two-year double-blind crossover trial published in 1986 examined the prophylactic effect of methylene blue in manic-depressive psychosis[1]. A related 1988 report addressed methylene blue in mania specifically[2].
Two things are worth noting about this era of work. The trials were small by modern standards, and the diagnostic frameworks and outcome measures of the period do not map cleanly onto current practice. But they were controlled and they were long, and a two-year crossover design in a relapsing illness is a genuinely demanding thing to run.
The 2017 Randomized Crossover Study
The modern anchor is a randomised crossover study published in the British Journal of Psychiatry, testing methylene blue for residual symptoms of bipolar disorder[3]. The framing matters: residual symptoms means the symptoms that persist in patients already treated and reasonably stable, which is a real and undertreated clinical problem.
The reported benefit was concentrated in depressive and anxiety symptoms rather than in mania or in preventing episodes. That is a narrower claim than “methylene blue treats bipolar disorder”, and it is the claim the evidence supports. Patients remained on their existing medication throughout.
The design is a strength. A crossover trial in a fluctuating illness lets each patient serve as their own control, which improves statistical efficiency in a small sample. It also introduces carryover concerns, which is why the effect being modest and symptom-domain-specific is more believable than a dramatic global result would have been.
What the 2024 Neuroimaging Trial Added
A 2024 randomized study used quantitative neuroimaging to examine the oxidative neurometabolic response to methylene blue in bipolar disorder, and found it altered compared with the comparison condition[4].
This is mechanistic work, and it should be read as such. It supports the idea that methylene blue does something measurable to brain oxidative metabolism, and that this something differs in bipolar disorder. It does not demonstrate that changing that metabolism improves how patients feel or function. Those are separate questions and the imaging study was not designed to answer the second one.
Still, it is unusual for a compound in this space to have any mechanistic human evidence at all, and it makes the clinical signal from 2017 more plausible than it would be standing alone.
The Interaction That Dominates Everything Here
Methylene blue is a potent monoamine oxidase inhibitor. Combining an MAO inhibitor with a serotonergic antidepressant is the classic recipe for serotonin syndrome, which can be severe and occasionally fatal.
People with bipolar disorder are frequently prescribed SSRIs, SNRIs, or other serotonergic agents. This means the population with the most relevant evidence behind them is also the population at highest risk from unsupervised use. The trials described above managed this with screening and monitoring that nobody has at home.
This is the single most important thing on this page. Anyone taking a serotonergic psychiatric medication should treat methylene blue as contraindicated outside of medical supervision.
How to Read This Body of Work Honestly
What exists: several controlled trials across four decades, a modern randomized crossover study with a specific symptom-domain result, and a mechanistic imaging study.
What does not exist: any large trial, any regulatory approval for a psychiatric indication, any evidence supporting methylene blue as monotherapy, and any established dose for this use outside a study protocol.
That combination describes a legitimate research thread, not a treatment. It is a better evidence base than most claims made about methylene blue, and it is still not enough to act on independently.
Frequently Asked Questions
Is methylene blue approved for bipolar disorder anywhere?
No. There is no regulatory approval for any psychiatric indication. The FDA-approved use of methylene blue injection is acquired methemoglobinemia. Everything described on this page is research use.
Was it tested as a replacement for mood stabilisers?
No, and this is a frequent misreading. In the modern trial it was added to existing treatment to target symptoms that persisted despite that treatment. Nothing in this literature supports stopping established medication.
Which symptoms responded?
The 2017 crossover study found its clearest signal in depressive and anxiety symptoms rather than in manic symptoms or relapse prevention. That is a specific and limited result, and reporting it as broader than that misrepresents the trial.
Why is the serotonin interaction such a big deal here specifically?
Because the overlap is almost total. Methylene blue is an MAO inhibitor, serotonin syndrome arises from combining MAO inhibition with serotonergic drugs, and serotonergic drugs are extremely common in the exact patient group this research concerns. The risk is not theoretical and it is not rare enough to ignore.
References
- A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry (1986). PMID 3091097
- Methylene blue in mania. Biol Psychiatry (1988). PMID 3069136
- Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. Br J Psychiatry (2017). PMID 27284082
- Altered oxidative neurometabolic response to methylene blue in bipolar disorder revealed by quantitative neuroimaging. J Affect Disord (2024). PMID 39019231
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
